stocktowatch
1 día hace
Good morning $CBDW and Its AI Chatbot Revolutionizing Customer Engagement for Public Companies
In a rapidly evolving business landscape, customer service and engagement are pivotal for the success of public companies. However, recent surveys have revealed a troubling gap in the market, with many investors and stakeholders expressing dissatisfaction over the lack of accessible and efficient support when researching public companies. Enter 1606 Corporation (CBDW), a forward-thinking technology company that is transforming the way public companies interact with their customers through its innovative AI-powered chatbot.
The Market Gap: A Survey of Investor Sentiment
A recent survey conducted among investors and stakeholders revealed a striking dissatisfaction with the current level of support available for those researching public companies. A significant portion of participants reported feeling frustrated with the limited access to timely information and the absence of immediate assistance when seeking answers about a company’s financials, corporate governance, or other essential data. The lack of responsive and efficient customer service options when navigating complex public company data is a pain point that has remained largely unaddressed—until now.
The survey underscores a broader issue: as public companies grow in size and complexity, they often struggle to provide personalized, real-time support for the increasing volume of questions they receive from analysts, investors, and the general public. This challenge is particularly acute when dealing with intricate financial documents, regulatory filings, and shareholder concerns, which require quick and accurate responses.
1606 Corporation’s AI Chatbot: A Solution to the Market’s Needs
Recognizing the need for a better approach, 1606 Corporation has developed an AI-powered chatbot designed to fill this critical gap. The company’s advanced technology is tailor-made for public companies, enabling them to provide immediate, accurate, and accessible support to a diverse range of stakeholders. The AI chatbot is capable of answering a wide array of questions related to corporate data, financial reports, governance policies, investor relations, and more—all through a simple and intuitive interface.
What makes the 1606 Corporation’s chatbot particularly revolutionary is its ability to handle complex queries efficiently, without the need for human intervention. Whether a user is seeking the latest quarterly earnings, information about the company’s board of directors, or insight into regulatory filings, the chatbot can provide these answers instantaneously. This is a game-changer for public companies that need to manage large volumes of inquiries without sacrificing the quality or speed of their customer service.
Enhancing Customer Service and Engagement
The integration of AI into customer service is not just about reducing costs—it’s about improving the overall experience for investors and other stakeholders. The chatbot’s 24/7 availability means that individuals can get the information they need at any time, without waiting for office hours or dealing with long response times. This level of accessibility can be especially beneficial for investors across different time zones or those managing large portfolios with tight decision-making timelines.
Moreover, the AI chatbot provides a seamless and personalized experience, learning from interactions to improve responses over time. By utilizing natural language processing (NLP) and machine learning algorithms, the chatbot can understand and process complex queries, providing more nuanced answers based on user intent. This continual learning process ensures that the chatbot evolves alongside a company’s needs and the changing demands of its stakeholders.
Driving Efficiency and Accessibility in Public Companies
1606 Corporation’s AI technology is not just enhancing customer service; it is also driving a new era of efficiency for public companies. Traditionally, managing inquiries from investors, analysts, and the public required significant manpower and time. With the AI chatbot, public companies can offload routine questions and tasks, freeing up their staff to focus on higher-priority matters. This streamlined approach not only saves time but also reduces operational costs, making it easier for public companies to scale their customer service efforts as they grow.
Additionally, the chatbot’s ability to present data in an easily digestible format improves accessibility. Financial reports and other complex information can be difficult to interpret for individuals without a deep understanding of the underlying data. The AI chatbot can break down these details in a more user-friendly way, helping investors and stakeholders gain clarity on important company metrics.
The Future of Customer Engagement in Public Companies
As AI continues to advance, 1606 Corporation is positioned at the forefront of a significant shift in how public companies engage with their customers. The company’s AI chatbot technology is not only addressing a key market gap but also setting a new standard for how companies should interact with their investors and stakeholders. The potential benefits of this technology are immense, from improving operational efficiency and customer satisfaction to fostering greater transparency and trust in the information shared by public companies.
In conclusion, 1606 Corporation (CBDW) is leading the charge in transforming customer service for public companies with its cutting-edge AI chatbot. By bridging the gap in support and engagement highlighted by recent surveys, 1606 is helping public companies offer faster, more accessible, and more personalized interactions with investors and stakeholders. This innovative technology is paving the way for a more efficient and transparent future in the corporate world, where AI and human expertise work together to drive success.
ProfitScout
2 días hace
This week's news from CBDW covering the great promise from their involvement with and investment plans for Adnexus Biotechnologies is impressive. The emerging AI technologies in the advancement of medical applications can lead to unparalleled benefits for so may people and businesses.
--------------------------------------------------------------------------------------------------
1606 Corp. Expresses Strong Support for Adnexus Biotechnologies' Groundbreaking AI Technology
SEATTLE, WA / ACCESSWIRE / December 18, 2024 / 1606 Corp. (OTC Pink:CBDW) is pleased to issue a statement in support of Adnexus Biotechnologies Inc., following the company's recent announcement of its revolutionary Neural Temporal Fingerprinting technology for personalized health monitoring. As part of our ongoing strategic partnership, 1606 Corp. recognizes the transformative potential of Adnexus' AI-driven advancements and looks forward to the continued development of these innovative solutions.
Adnexus' Groundbreaking Innovation
The Neural Temporal Fingerprinting technology introduced by Adnexus leverages AI-driven analysis of EEG and ECG signals to deliver unparalleled insights into neurological and cardiovascular health. Key aspects of the technology include:
Neurological Prediction: AI-powered analysis of EEG data to detect early signs of neurological conditions such as Alzheimer's, Parkinson's, and PTSD.
Cardiovascular Risk Assessment: Analyzing ECG signals to assess heart health, identify arrhythmias, and predict risks of heart failure and myocardial infarction.
Integrated EEG/ECG Analysis: Merging both neurological and cardiovascular data to better understand the complex interplay between brain and heart health.
Enhanced PTSD Detection: Identifying emotional and autonomic dysregulations to provide more effective treatments for trauma survivors.
1606 Corp. views Adnexus' breakthrough as a critical step in the future of personalized medicine and real-time health monitoring, particularly as wearables become an increasingly integral part of healthcare. We believe this innovation will significantly disrupt the growing AI-driven healthcare market, positioning both Adnexus and 1606 Corp. for future success.
Austen Lambrecht, CEO of 1606 Corp., commented:
"Adnexus' latest development in Neural Temporal Fingerprinting is a powerful demonstration of the company's ability to drive innovation in the healthcare sector. As a strategic partner, we are excited to support Adnexus in bringing this groundbreaking technology to market. We see tremendous potential for these AI-powered solutions to redefine the way neurological and cardiovascular conditions are diagnosed and treated, and we look forward to continuing our collaboration with Adnexus in this transformative space."
Commitment to Innovation and Growth
The potential strategic investment by 1606 Corp. in Adnexus aligns with our long-term vision to invest in cutting-edge AI health technologies that are poised for significant growth. Adnexus previously signed a Letter of Intent with 1606 Corp. for a strategic investment by 1606 Corp. in Adnexus. The LOI terminated on November 28, 2024 but the parties are still moving forward to close the transaction. We are confident that Adnexus' focus on AI-driven diagnostic tools and personalized health insights will play an essential role in advancing healthcare practices and improving patient outcomes.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit cbdw.ai.
Industry Information
The global AI market, valued at $428 billion in 2022, is anticipated to reach $2.25 trillion by 2030, with a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%. The sector is expected to employ 97 million individuals by 2025[1], reflecting its expansive and significant impact. This potential growth presents a compelling opportunity for investors and industry professionals interested in the AI sector.
The global wearable health technology market was valued at $70.3 billion in 2024 and is projected to reach $152.8 billion by 2029, growing at a CAGR of 16.4%[2]. This growth is driven by advancements in sensor technology, AI integration, and increasing consumer demand for real-time health monitoring. Adnexus' emphasis on continuous health monitoring through wearable devices aligns directly with this market trend, particularly as consumers and healthcare providers look for tools to proactively manage chronic conditions and predict health risks.
AI-Powered Wearables: Wearable health devices powered by AI are increasingly being used to monitor vital signs such as heart rate, blood pressure, ECG, and EEG. Adnexus' hybrid model combining EEG and ECG for continuous health monitoring could place it in a strong position within the rapidly growing wearable health tech market.
The global AI in healthcare market was valued at $11.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.2% from 2023 to 2030[3]. This growth is driven by the increasing demand for advanced diagnostic tools, predictive analytics, and personalized treatments, which align with Adnexus' focus on AI-powered health insights through EEG and ECG data.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. The Company does not undertake any obligation to update forward-looking statements except as required by law.
Contact Information
Austen Lambrecht
CEO
austen@1606corp.com
[1]MarketsandMarkets, "Artificial Intelligence Market by Technology (Machine Learning, NLP, Computer Vision), End-User Industry (Healthcare, BFSI, Automotive, Retail, IT & Telecom), and Region - Global Forecast to 2030," 2023; PwC, "Global Artificial Intelligence Study: Exploiting the AI Revolution," 2022; McKinsey & Company, "The State of AI in 2023," 2023.
[2] Grand View Research, "Wearable Medical Devices Market Size, Share & Trends Analysis Report by Product (Smartwatches, Fitness Bands, Patches), by Application (Cardiovascular, Sleep Monitoring), by Region, and Segment Forecasts, 2024 - 2029," 2023; Statista, "Global Wearable Health Technology Market Value Forecast," 2023; Frost & Sullivan, "Wearable Health Tech: The Next Frontier in Healthcare Innovation," 2023.
[3] Fortune Business Insights, "Artificial Intelligence in Healthcare Market Size, Share & Trends Analysis Report by Offering, by Technology, by Application, by End User, and Segment Forecasts, 2023 - 2030," 2023; ResearchAndMarkets, "AI in Healthcare Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2023 - 2030," 2023; Grand View Research, "Artificial Intelligence in Healthcare Market Size, Share & Trends Analysis Report by Technology (Machine Learning, Natural Language Processing), by Application (Diagnostics, Drug Discovery), by End-Use, and Segment Forecasts, 2023 - 2030," 2023.
SOURCE: 1606 Corp.
View the original press release on accesswire.com
Trooperstocks
3 días hace
NEWS: Full Press Release: 1606 Corp. Expresses Strong Support for Adnexus Biotechnologies' Groundbreaking AI Technology
1606 Corp
Wed, December 18, 2024 at 8:00 AM EST
In This Article:
CBDW
+3.45%
SEATTLE, WA / ACCESSWIRE / December 18, 2024 / 1606 Corp. (OTC Pink:CBDW) is pleased to issue a statement in support of Adnexus Biotechnologies Inc., following the company's recent announcement of its revolutionary Neural Temporal Fingerprinting technology for personalized health monitoring. As part of our ongoing strategic partnership, 1606 Corp. recognizes the transformative potential of Adnexus' AI-driven advancements and looks forward to the continued development of these innovative solutions.
Adnexus' Groundbreaking Innovation
The Neural Temporal Fingerprinting technology introduced by Adnexus leverages AI-driven analysis of EEG and ECG signals to deliver unparalleled insights into neurological and cardiovascular health. Key aspects of the technology include:
Neurological Prediction: AI-powered analysis of EEG data to detect early signs of neurological conditions such as Alzheimer's, Parkinson's, and PTSD.
Cardiovascular Risk Assessment: Analyzing ECG signals to assess heart health, identify arrhythmias, and predict risks of heart failure and myocardial infarction.
Integrated EEG/ECG Analysis: Merging both neurological and cardiovascular data to better understand the complex interplay between brain and heart health.
Enhanced PTSD Detection: Identifying emotional and autonomic dysregulations to provide more effective treatments for trauma survivors.
1606 Corp. views Adnexus' breakthrough as a critical step in the future of personalized medicine and real-time health monitoring, particularly as wearables become an increasingly integral part of healthcare. We believe this innovation will significantly disrupt the growing AI-driven healthcare market, positioning both Adnexus and 1606 Corp. for future success.
Austen Lambrecht, CEO of 1606 Corp., commented:
"Adnexus' latest development in Neural Temporal Fingerprinting is a powerful demonstration of the company's ability to drive innovation in the healthcare sector. As a strategic partner, we are excited to support Adnexus in bringing this groundbreaking technology to market. We see tremendous potential for these AI-powered solutions to redefine the way neurological and cardiovascular conditions are diagnosed and treated, and we look forward to continuing our collaboration with Adnexus in this transformative space."
Commitment to Innovation and Growth
The potential strategic investment by 1606 Corp. in Adnexus aligns with our long-term vision to invest in cutting-edge AI health technologies that are poised for significant growth. Adnexus previously signed a Letter of Intent with 1606 Corp. for a strategic investment by 1606 Corp. in Adnexus. The LOI terminated on November 28, 2024 but the parties are still moving forward to close the transaction. We are confident that Adnexus' focus on AI-driven diagnostic tools and personalized health insights will play an essential role in advancing healthcare practices and improving patient outcomes.
About 1606 Corp.
1606 Corp. stands at the forefront of technological innovation, particularly in AI Chatbots. Our mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. We are dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
As a visionary enterprise, 1606 Corp. equips businesses with the advanced tools they need to excel in the competitive digital landscape. Our commitment to innovation and quality positions us as a leader in the field, driving the industry forward and setting new benchmarks for success and customer satisfaction.
For more information, please visit cbdw.ai.
Industry Information
The global AI market, valued at $428 billion in 2022, is anticipated to reach $2.25 trillion by 2030, with a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%. The sector is expected to employ 97 million individuals by 2025[1], reflecting its expansive and significant impact. This potential growth presents a compelling opportunity for investors and industry professionals interested in the AI sector.
The global wearable health technology market was valued at $70.3 billion in 2024 and is projected to reach $152.8 billion by 2029, growing at a CAGR of 16.4%[2]. This growth is driven by advancements in sensor technology, AI integration, and increasing consumer demand for real-time health monitoring. Adnexus' emphasis on continuous health monitoring through wearable devices aligns directly with this market trend, particularly as consumers and healthcare providers look for tools to proactively manage chronic conditions and predict health risks.
AI-Powered Wearables: Wearable health devices powered by AI are increasingly being used to monitor vital signs such as heart rate, blood pressure, ECG, and EEG. Adnexus' hybrid model combining EEG and ECG for continuous health monitoring could place it in a strong position within the rapidly growing wearable health tech market.
The global AI in healthcare market was valued at $11.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.2% from 2023 to 2030[3]. This growth is driven by the increasing demand for advanced diagnostic tools, predictive analytics, and personalized treatments, which align with Adnexus' focus on AI-powered health insights through EEG and ECG data.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. The Company does not undertake any obligation to update forward-looking statements except as required by law.
Contact Information
Austen Lambrecht
CEO
austen@1606corp.com
[1]MarketsandMarkets, "Artificial Intelligence Market by Technology (Machine Learning, NLP, Computer Vision), End-User Industry (Healthcare, BFSI, Automotive, Retail, IT & Telecom), and Region - Global Forecast to 2030," 2023; PwC, "Global Artificial Intelligence Study: Exploiting the AI Revolution," 2022; McKinsey & Company, "The State of AI in 2023," 2023.
[2] Grand View Research, "Wearable Medical Devices Market Size, Share & Trends Analysis Report by Product (Smartwatches, Fitness Bands, Patches), by Application (Cardiovascular, Sleep Monitoring), by Region, and Segment Forecasts, 2024 - 2029," 2023; Statista, "Global Wearable Health Technology Market Value Forecast," 2023; Frost & Sullivan, "Wearable Health Tech: The Next Frontier in Healthcare Innovation," 2023.
[3] Fortune Business Insights, "Artificial Intelligence in Healthcare Market Size, Share & Trends Analysis Report by Offering, by Technology, by Application, by End User, and Segment Forecasts, 2023 - 2030," 2023; ResearchAndMarkets, "AI in Healthcare Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts, 2023 - 2030," 2023; Grand View Research, "Artificial Intelligence in Healthcare Market Size, Share & Trends Analysis Report by Technology (Machine Learning, Natural Language Processing), by Application (Diagnostics, Drug Discovery), by End-Use, and Segment Forecasts, 2023 - 2030," 2023.
SOURCE: 1606 Corp.
View the original press release on accesswire.com
Trooperstocks
4 días hace
$CBDW NEWS: Adnexus Biotechnologies Unveils Neural Temporal Fingerprinting for Personalized Health Monitoring Using Artificial Intelligence
Adnexus Biotechnologies Inc.
Tue, December 17, 2024 at 7:00 AM EST
In This Article:
CBDW
+1.45%
DALLAS, TX / ACCESSWIRE / December 17, 2024 / Adnexus Biotechnologies Inc. is proud to announce the launch of AI-Driven Neural Temporal Fingerprinting, a groundbreaking technology designed to predict and monitor neurological and cardiovascular conditions with unparalleled accuracy. This innovation is developed under the umbrella of the company's advanced AI platform, Sutra. The brain and heart of each person send signals with patterns of long and short signals, and EEG and ECG read these signals. Neural Temporal Fingerprinting decodes these signals to understand messages about a person's health, translating complex signals into understandable health insights.
Key Innovations in Neural Temporal Fingerprinting:
Neurological Prediction through EEG: This system utilizes cutting-edge AI, including a combination of Convolutional Neural Networks (CNNs) and Graph Neural Networks (GNNs), to interpret EEG data to detect early signs of neurological conditions such as Alzheimer's, Parkinson's disease, Epilepsy, Encephalopathy, and PTSD. It provides clinicians with predictive scores and actionable insights for therapeutic interventions.
Cardiovascular Risk Assessment via ECG: This technology analyzes electrocardiogram (ECG) signals to assess arrhythmias, myocardial infarction, and heart failure risks. It focuses on heart rate variability and cardiac rhythm abnormalities, enabling precise risk stratification and continuous monitoring.
Integrated EEG/ECG Analysis: A unique hybrid model merges EEG and ECG data to evaluate brain-heart interactions. This combined analysis provides valuable insights into conditions influenced by both systems.
Enhanced PTSD Prediction: A specialized module examines both neural and cardiac signals to identify emotional and autonomic dysregulations associated with PTSD, facilitating personalized treatment strategies.
Real-Time Monitoring through Wearables: The system supports continuous health monitoring via wearable devices, enabling proactive health management in clinical and home environments.
Dr. Gaurav Chandra, CEO of Adnexus Biotechnologies, stated, "We're excited to integrate this breakthrough into our Sutra AI platform, with its tremendous potential for early disease detection and personalized treatment strategies based on individual neural signatures. By understanding the neuronal feedback loops associated with PTSD, we aim to identify emotional triggers and develop targeted interventions that can alleviate symptoms and aid recovery. This innovation has the potential to revolutionize PTSD management-from diagnosis to continuous monitoring and therapy-and offers promising applications for trauma survivors, soldiers, and conditions like dementia, seizures, and traumatic brain injury."
He continued this technological edge, positioning Adnexus Biotechnologies Inc. as a health tech leader with the potential to increase value through innovation and patents. Our diverse patent portfolio resulting from our AI Platform, Sutra, opens new markets, strengthens existing ones, and directly impacts value by driving sales and market penetration."
Dr. Kirsten Bischof, a co-inventor of this innovation and member of Adnexus Biotechnologies' Advisory Board, added, "By integrating EEG and ECG data, Neurotemporal Fingerprinting provides a more comprehensive view of patient health, addressing both neural and cardiac systems. This approach may lead to earlier detection and better management of health issues, whether they are acute or chronic, ultimately reducing healthcare costs and improving patient outcomes. She added, "Integrating these signals through Neurotemporal Fingerprinting allows for proactive rather than reactive healthcare. This shift will decrease the need for costly treatments by identifying problems before they escalate."
Strategic Developments: Adnexus has taken a significant step towards its future growth and innovation by signing a Letter of Intent with 1606 Corp (OTC: CBDW) for a strategic investment. The initial LOI period has lapsed, but the parties are still moving forward with a final deal. This partnership, a testament to our commitment to advancing healthcare, sets the stage for expanded growth and innovation in AI-driven health solutions, instilling confidence in our stakeholders.
About Adnexus Biotechnologies Inc.: Adnexus stands at the forefront of biotechnology, employing AI to revolutionize drug discovery, infectious disease management, and neurodegenerative research. Our focus is on advancing our HIV drugs to develop groundbreaking treatments. Visit www.adnexusbiotech.com for more details.
The AI Platform Sutra is central to the company's innovation, now expanding to:
Identify Disease Biomarkers: Allowing for early detection and more targeted interventions.
Advance Personalized Medicine
Industry Insights:
The global wearable health technology market was valued at $70.3 billion in 2024 and is projected to reach $152.8 billion by 2029, growing at a CAGR of 16.4%. Advancements in sensor technology, AI integration, and increasing consumer demand for real-time health monitoring drive this growth. Adnexus' emphasis on continuous health monitoring through wearable devices aligns directly with this market trend, particularly as consumers and healthcare providers look for tools to proactively manage chronic conditions and predict health risks.
AI-Powered Wearables: AI-powered wearable health devices are increasingly being used to monitor vital signs such as heart rate, blood pressure, ECG, and EEG. Adnexus' hybrid model, which combines EEG and ECG for continuous health monitoring, could place it in a strong position within the rapidly growing wearable health tech market.
The global AI in healthcare market was valued at $11.8 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 37.2% from 2023 to 2030. This growth is driven by the increasing demand for advanced diagnostic tools, predictive analytics, and personalized treatments, which align with Adnexus' focus on AI-powered health insights through EEG and ECG data.
Forward-Looking Statements
This press release includes forward-looking statements under federal securities laws, including projections and expectations regarding business developments, operations, and market conditions. These statements are identified by terms such as "should," "may," "intends," "anticipates," and others. While based on reasonable assumptions, results may differ due to various risks and uncertainties. Please review cautionary statements and disclosures in our filings with the SEC. Adnexus is not obligated to update forward-looking statements except as required by law.
For inquiries, please get in touch with Dr. Gaurav Chandra, CEO, gaurav.chandra@adnexusbiotech.com
https://www.adnexusbiotech.com
https://www.cbdw.ai
Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
resx18
1 día hace
AveragePenny
2 días hace
Hot Features
Premium
